JC20 Rec'd PCT/PTO 2 6 SEP 2005

Sheet 1 of 1

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 05-765	Serial No. To Be Assigned		
·		Applicant: Starck et al.			
		Filing Date:	Group:		
		Herewith	To Be Assigned		

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
ISYI	Al	4,624,963 A	November 25, 1986	Kruse et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Trans Yes	lation No
	A2	WO 04/20272 A	December 22, 1994	PCT				X
	A3	WO 98/01428 A	January 15, 1998	PCT				×
	A4	FP 0 445 781 A	September 11, 1991	EPO			_	X
	A3	EP 0 022 317 A	January 14, 1981	EPO				X
	Δ6	JP 1 005766 A	April 13, 1989	Japan				×

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Δ7	Chemical Patents Index, Documentation Abstracts Journal, Section Ch, Week 9627, Class 802, AN 96-366523. XP002241135		
	A8	Nilsson, i. et al., Acta Chem. Scand. Ser. B, 1965, Vol. 39, No. 7, p. 331-346.		
	A9	Bell, M. et al., J. Med. Chem., 1991, Vol. 34, No. 3, pp. 1099-1110.		
	A10	Hotzel, C. et al., "Design, Synthesis, DNA-Binding and Cytotoxicity Evaluation of New Potential Combilexines", European Journal of Medicinal Chemistry, 2002, Vol. 37, No. 5, pp. 367-378.		
EXAMINER /Shawquia Young/		hawquia Young/	DATE CONSIDERED 11/21/2007	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.